In the wake of the increase in Current Liabilities in the third quarter 2012, Quick Ratio fell to 0.01 below Ceres Ventures, Inc. average.

Within Major Pharmaceutical Preparations industry 177 other companies have achieved higher Quick Ratio than Ceres Ventures in third quarter 2012. While Quick Ratio total ranking in the third quarter 2012 has deteriorated compared to the prior quarter from 3134 to 3747.

Explain Quick Ratio?
How much Cash & cash equivalents CEVE�s has?
What are CEVE�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

CEVE Quick Ratio	(Sep 30 2012) Q3	(Jun 30 2012) Q2	(Mar 31 2012) Q1	(Dec 31 2011) Q4	(Sep 30 2011) Q3
Y / Y Current Liabilities Change	51.39 %	11.96 %	388 %	-	-
Y / Y Cash & cash equivalent Change	-97.01 %	-86.78 %	-98.92 %	-	-
Quick Ratio MRQ	0.01	0.12	0	0.21	0.71
CEVE's Total Ranking	# 3747	# 3134	# 3685	# 0	#
Seq. Current Liabilities Change	44.03 %	-57.17 %	2.05 %	140.47 %	6.52 %
Seq. Cash & cash equivalent Change	-83.14 %	1983.27 %	-98.8 %	-29.23 %	-25.39 %

Quick Ratio third quarter 2012 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 178
Healthcare Sector	# 459
Overall Market	# 3747

Quick Ratio Statistics
High	Average	Low
0.21	0.09	0
(Dec 31 2011)		(Mar 31 2012)

Financial Statements
Ceres Ventures's Current Liabilities	$ 0 Millions	Visit CEVE's Balance sheet
Ceres Ventures's Cash & cash equivalent	$ 0 Millions	Visit CEVE's Balance sheet
Source of CEVE's Sales		Visit CEVE's Sales by Geography

Cumulative Ceres Ventures's Quick Ratio

CEVE's Quick Ratio for the trailling 12 Months

CEVE Quick Ratio	(Sep 30 2012) 12 Months	(Jun 30 2012) 12 Months	(Mar 31 2012) 12 Months	(Dec 31 2011) 12 Months	(Sep 30 2011) 12 Months
Y / Y Current Liabilities TTM Growth	204.04 %	379.29 %	1251.75 %	-	-
Y / Y Cash & cash equivalent TTM Growth	-70.5 %	-11.08 %	287.49 %	-	-
Quick Ratio TTM	0.09	0.19	0.32	0.56	0.91
Total Ranking TTM	# 959	# 642	# 0	# 0	#
Seq. Current Liabilities TTM Growth	7.44 %	1.65 %	40.26 %	98.49 %	69.36 %
Seq. Cash & cash equivalent TTM Growth	-51.24 %	-38.06 %	-20.34 %	22.62 %	46.97 %

Quick ratio ranking by company, industry and sector >> Back to CEVE Financial Strength Comparisons >> Go to Compare CEVE Quick Ratio to its Competitors

On the trailing twelve months basis Due to jump in Current Liabilities in the Q3 2012 to $0.34 millions, cumulative Quick Ratio decreased to 0.09 above the CEVE average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 18 other companies have achieved higher Quick Ratio than Ceres Ventures. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2012 from 642 to 959.

Explain Quick Ratio?
How much Cash & cash equivalents CEVE�s has?
What are CEVE�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 19
Healthcare Sector	# 77
Within the Market	# 959

trailing twelve months Quick Ratio Statistics
High	Average	Low
0.09	0.08	0.08
(Sep 30 2012)		(Jun 30 2012)

Companies with similar Quick Ratio in the quarter ending Sep 30 2012, within Major Pharmaceutical Preparations Industry	Quick Ratio	Sep 30 2012 MRQ Cash & cash equivalent	Sep 30 2012 MRQ Current Liabilities
Therapeuticsmd Inc	0.03	$ 0.154 Millions	$ 4.428 Millions
Rezolute Inc	0.03	$ 0.000 Millions	$ 0.016 Millions
Protalex Inc	0.02	$ 0.058 Millions	$ 2.351 Millions
Gt Biopharma Inc	0.02	$ 0.061 Millions	$ 2.532 Millions
Silo Pharma Inc	0.02	$ 0.000 Millions	$ 0.014 Millions
Fibrocell Science, Inc.	0.02	$ 0.118 Millions	$ 6.234 Millions
Innovation Pharmaceuticals Inc	0.02	$ 0.125 Millions	$ 7.534 Millions
Cervomed Inc	0.02	$ 0.157 Millions	$ 9.529 Millions
Ceres Ventures, Inc.	0.01	$ 0.005 Millions	$ 0.344 Millions
Emmis Acquisition Corp	0.01	$ 0.628 Millions	$ 46.486 Millions
Cytodyn inc	0.01	$ 0.066 Millions	$ 5.030 Millions
REGENEREX PHARMA, INC.	0.01	$ 0.004 Millions	$ 0.334 Millions
Abeona Therapeutics Inc	0.01	$ 0.106 Millions	$ 8.986 Millions
Protokinetix Incorporated	0.01	$ 0.005 Millions	$ 0.469 Millions
Aytu Biopharma Inc	0.01	$ 0.000 Millions	$ 0.014 Millions
Abvc Biopharma Inc	0.01	$ 0.013 Millions	$ 1.946 Millions
Propanc Biopharma Inc	0.01	$ 0.001 Millions	$ 0.179 Millions
Opiant Pharmaceuticals Inc	0.01	$ 0.002 Millions	$ 0.357 Millions
Citius Pharmaceuticals Inc	0.00	$ 0.000 Millions	$ 0.021 Millions
Vistagen Therapeutics Inc	0.00	$ 0.013 Millions	$ 2.945 Millions
Generex Biotechnology Corp	0.00	$ 0.037 Millions	$ 8.177 Millions
Kaya Holdings Inc	0.00	$ 0.009 Millions	$ 1.979 Millions
Dmk Pharmaceuticals Corporation	0.00	$ 0.010 Millions	$ 2.492 Millions
Hst Global Inc	0.00	$ 0.001 Millions	$ 0.399 Millions
Enliven Therapeutics Inc	0.00	$ 0.008 Millions	$ 2.720 Millions
Northwest Biotherapeutics Inc	0.00	$ 0.111 Millions	$ 36.153 Millions

Date modified: 2026-09-08T15:07:17+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.